Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
A deeper look into infections among myeloma patients treated with Daratumumab or Belantamab mafodotin
Guldane Cengiz Seval, MD
Assoc. Prof.
Ankara University School of Medicine, Department of Hematology, Ankara, Turkey
Belamaf Pom Dex | Dara combos | |
Number | 9 | 127 |
Median Age, years (range) | 62 (52-70) | 56 (32-78) |
Median Prior lines of therapy | 2 (2-7) | 2 (0-7) |
ISS I/II/III | 2/-/7 | 43/39/42 |
PI refractory | - | 44/127 |
IMID refractory | 9 | 70/127 |
PI and IMID refractory | - | 28/127 |
Treatment duration mo | 24 (3-35) | 13 (0-68) |
Best response CR/VGPR/PR/PD | 6/-/3/- | 50/18/15/44 |
Grade 3-4 Lymphopenia | 5 (55%) | 97 (77%) |
Hypogamaglobulinemia | 4 (44%) | 91 (72%) |
Grade 3-4 infections | 2 (22%) | 53/127 |
Grade 5 infections | 0 | 5/127 |
CMV reactivation episodes | 0 | 22/127 |
IV Immunoglobulin use | 2 (1-9) | 1 (0-9) |